Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2024

Open Access 01-12-2024 | Breast Cancer | Research

Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis

Authors: Zi-qiong Wang, Zhi-xuan Wu, Zong-pan Wang, Jing-xia Bao, Hao-dong Wu, Di-yan Xu, Hong-feng Li, Yi-Yin Xu, Rong-xing Wu, Xuan-xuan Dai

Published in: BMC Cancer | Issue 1/2024

Login to get access

Abstract

NUP155 is reported to be correlated with tumor development. However, the role of NUP155 in tumor physiology and the tumor immune microenvironment (TIME) has not been previously examined. This study comprehensively investigated the expression, immunological function, and prognostic significance of NUP155 in different cancer types. Bioinformatics analysis revealed that NUP155 was upregulated in 26 types of cancer. Additionally, NUP155 upregulation was strongly correlated with advanced pathological or clinical stages and poor prognosis in several cancers. Furthermore, NUP155 was significantly and positively correlated with DNA methylation, tumor mutational burden, microsatellite instability, and stemness score in most cancers. Additionally, NUP155 was also found to be involved in TIME and closely associated with tumor infiltrating immune cells and immunoregulation-related genes. Functional enrichment analysis revealed a strong correlation between NUP155 and immunomodulatory pathways, especially antigen processing and presentation. The role of NUP155 in breast cancer has not been examined. This study, for the first time, demonstrated that NUP155 was upregulated in breast invasive carcinoma (BRCA) cells and revealed its oncogenic role in BRCA using molecular biology experiments. Thus, our study highlights the potential value of NUP155 as a biomarker in the assessment of prognostic prediction, tumor microenvironment and immunotherapeutic response in pan-cancer.
Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef
2.
Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135(5):584–90.PubMedCrossRef
3.
Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29–39.PubMedCrossRef
4.
Wieder T, Eigentler T, Brenner E, Röcken M. Immune checkpoint blockade therapy. J Allergy Clin Immunol. 2018;142(5):1403–14.PubMedCrossRef
5.
6.
7.
Hurt E, Beck M. Towards understanding nuclear pore complex architecture and dynamics in the age of integrative structural analysis. Curr Opin Cell Biol. 2015;34:31–8.PubMedCrossRef
8.
9.
Jamali T, Jamali Y, Mehrbod M, Mofrad M. Nuclear pore complex: biochemistry and biophysics of nucleocytoplasmic transport in health and disease. Int Rev cell Mol Biology. 2011;287:233–86.CrossRef
10.
Sun J, Shi Y, Yildirim E. The nuclear pore complex in cell type-specific chromatin structure and gene regulation. Trends Genet. 2019;35(8):579–88.PubMedCrossRef
11.
Sakuma S, Raices M, Borlido J, Guglielmi V, Zhu E, D’Angelo M. Inhibition of nuclear pore complex formation selectively induces cancer cell death. Cancer Discov. 2021;11(1):176–93.PubMedCrossRef
12.
Jans D, Martin A, Wagstaff K. Inhibitors of nuclear transport. Curr Opin Cell Biol. 2019;58:50–60.PubMedCrossRef
13.
Taylor J, Sendino M, Gorelick A, Pastore A, Chang M, Penson A, Gavrila E, Stewart C, Melnik E, Herrejon Chavez F, et al. Altered nuclear export signal recognition as a driver of oncogenesis. Cancer Discov. 2019;9(10):1452–67.PubMedPubMedCentralCrossRef
14.
Kosinski J, Mosalaganti S, von Appen A, Teimer R, DiGuilio A, Wan W, Bui K, Hagen W, Briggs J, Glavy J, et al. Molecular architecture of the inner ring scaffold of the human nuclear pore complex. Sci (New York NY). 2016;352(6283):363–5.ADSCrossRef
15.
von Appen A, Kosinski J, Sparks L, Amanda DG, Vollmer B. In situ structural analysis of the human nuclear pore complex. Nature. 2015;526:140.ADSCrossRef
16.
De Magistris P, Tatarek-Nossol M, Dewor M, Antonin W. A self-inhibitory interaction within Nup155 and membrane binding are required for nuclear pore complex formation. J Cell Sci. 2018;131(1):jcs208538.PubMed
17.
Zhang X, Chen S, Yoo S, Chakrabarti S, Zhang T, Ke T, Oberti C, Yong S, Fang F, Li L, et al. Mutation in nuclear pore component NUP155 leads to atrial fibrillation and early sudden cardiac death. Cell. 2008;135(6):1017–27.PubMedCrossRef
18.
Savci-Heijink C, Halfwerk H, Koster J, van de Vijver M. A novel gene expression signature for bone metastasis in breast carcinomas. Breast Cancer Res Treat. 2016;156(2):249–59.PubMedPubMedCentralCrossRef
19.
Engqvist H, Parris T, Kovács A, Rönnerman E, Sundfeldt K, Karlsson P, Helou K. Validation of Novel Prognostic biomarkers for early-stage Clear-Cell, endometrioid and mucinous ovarian carcinomas using immunohistochemistry. Front Oncol. 2020;10:162.PubMedPubMedCentralCrossRef
20.
Holzer K, Ori A, Cooke A, Dauch D, Drucker E, Riemenschneider P, Andres-Pons A, DiGuilio A, Mackmull M, Baßler J, et al. Nucleoporin Nup155 is part of the p53 network in liver cancer. Nat Commun. 2019;10(1):2147.ADSPubMedPubMedCentralCrossRef
21.
Boyault S, Rickman D, de Reyniès A, Balabaud C, Rebouissou S, Jeannot E, Hérault A, Saric J, Belghiti J, Franco D, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology (Baltimore, MD). 2007;45(1):42–52.PubMedCrossRef
22.
Basit A, Cho M, Kim E, Kwon D, Kang S, Lee J. The cGAS/STING/TBK1/IRF3 innate immunity pathway maintains chromosomal stability through regulation of p21 levels. Exp Mol Med. 2020;52(4):643–57.PubMedPubMedCentralCrossRef
23.
Goldman MJ, Craft B, Hastie M, Repečka K, McDade F, Kamath A, Banerjee A, Luo Y, Rogers D, Brooks AN, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675–8.PubMedPubMedCentralCrossRef
24.
Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M, Netto GJ, Qin ZS, Kumar S, Manne U, et al. UALCAN: an update to the integrated cancer data analysis platform. Neoplasia. 2022;25:18–27.PubMedPubMedCentralCrossRef
25.
Sun D, Wang J, Han Y, Dong X, Ge J, Zheng R, Shi X, Wang B, Li Z, Ren P, et al. TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment. Nucleic Acids Res. 2021;49(D1):D1420-1430.PubMedCrossRef
26.
Laue C, Papazova E, Pannenbeckers A, Schrezenmeir J. Effect of a probiotic and a Synbiotic on Body Fat Mass, Body Weight and traits of metabolic syndrome in individuals with abdominal overweight: a human, Double-Blind, randomised, controlled clinical study. Nutrients. 2023;15(13):3039.PubMedPubMedCentralCrossRef
27.
Wenthe J, Eriksson E, Hellström AC, Moreno R, Ullenhag G, Alemany R, Lövgren T, Loskog A. Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models. J Transl Med. 2023;21(1):506.PubMedPubMedCentralCrossRef
28.
El-Adili F, Lui JK, Najem M, Farina G, Trojanowska M, Sam F, Bujor AM. Periostin overexpression in scleroderma cardiac tissue and its utility as a marker for disease complications. Arthritis Res Ther. 2022;24(1):251.PubMedPubMedCentralCrossRef
29.
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, et al. The landscape of somatic copy-number alteration across human cancers. Nature. 2010;463(7283):899–905.ADSPubMedPubMedCentralCrossRef
30.
Bonneville R, Krook MA, Kautto EA, Miya J, Wing MR, Chen HZ, Reeser JW, Yu L, Roychowdhury S. Landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. 2017;2017:PO.17.00073.PubMed
31.
Sacks D, Baxter B, Campbell BCV, Carpenter JS, Cognard C, Dippel D, Eesa M, Fischer U, Hausegger K, Hirsch JA, et al. Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke. Int J Stroke. 2018;13(6):612–32.PubMed
32.
33.
Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, Sun Y, Jacobsen A, Sinha R, Larsson E, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1.PubMedPubMedCentralCrossRef
34.
Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.PubMedCrossRef
35.
Liu C-J, Hu F-F, Xia M-X, Han L, Zhang Q, Guo A-Y. GSCALite: a web server for gene set cancer analysis. Bioinformatics. 2018;34(21):3771–2.PubMedCrossRef
36.
Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P, Franz M, Grouios C, Kazi F, Lopes CT, et al. The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. Nucleic Acids Res. 2010;38(suppl2):W214-220.PubMedPubMedCentralCrossRef
37.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–8.PubMedCrossRef
38.
Steuer C, Ramalingam S. Tumor mutation burden: leading immunotherapy to the era of precision medicine? J Clin Oncol. 2018;36(7):631–2.PubMedCrossRef
39.
Ji P, Gong Y, Jin ML, Wu HL, Guo LW, Pei YC, Chai WJ, Jiang YZ, Liu Y, Ma XY, et al. In vivo multidimensional CRISPR screens identify Lgals2 as an immunotherapy target in triple-negative breast cancer. Sci Adv. 2022;8(26):eabl8247.PubMedPubMedCentralCrossRef
40.
41.
Kim S, Fernandez-Martinez J, Nudelman I, Shi Y, Zhang W, Raveh B, Herricks T, Slaughter B, Hogan J, Upla P, et al. Integrative structure and functional anatomy of a nuclear pore complex. Nature. 2018;555(7697):475–82.ADSPubMedPubMedCentralCrossRef
42.
43.
Franz C, Askjaer P, Antonin W, Iglesias CL, Haselmann U, Schelder M, de Marco A, Wilm M, Antony C, Mattaj IW. Nup155 regulates nuclear envelope and nuclear pore complex formation in nematodes and vertebrates. Embo j. 2005;24(20):3519–31.PubMedPubMedCentralCrossRef
44.
Yokoyama T, Yukuhiro M, Iwasaki Y, Tanaka C, Sankoda K, Fujiwara R, Shibuta A, Higashi T, Motoyama K, Arima H, et al. Identification of candidate molecular targets of the novel antineoplastic antimitotic NP-10. Sci Rep. 2019;9(1):16825.ADSPubMedPubMedCentralCrossRef
45.
Colussi C, Grassi C. Epigenetic regulation of neural stem cells: the emerging role of nucleoporins. Stem Cells. 2021;39(12):1601–14.PubMedCrossRef
46.
Jacinto FV, Benner C, Hetzer MW. The nucleoporin Nup153 regulates embryonic stem cell pluripotency through gene silencing. Genes Dev. 2015;29(12):1224–38.PubMedPubMedCentralCrossRef
47.
Toda T, Hsu JY, Linker SB, Hu L, Schafer ST, Mertens J, Jacinto FV, Hetzer MW, Gage FH. Nup153 interacts with Sox2 to enable bimodal gene regulation and maintenance of neural progenitor cells. Cell Stem Cell. 2017;21(5):618-634e617.PubMedCrossRef
48.
49.
Domingo-Reinés J, Montes R, Garcia-Moreno A, Gallardo A, Sanchez-Manas JM, Ellson I, Lamolda M, Calabro C, López-Escamez JA, Catalina P, et al. The pediatric leukemia oncoprotein NUP98-KDM5A induces genomic instability that may facilitate malignant transformation. Cell Death Dis. 2023;14(6):357.PubMedPubMedCentralCrossRef
50.
Bertrums EJM, Smith JL, Harmon L, Ries RE, Wang YJ, Alonzo TA, Menssen AJ, Chisholm KM, Leonti AR, Tarlock K, et al. Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia. Haematologica. 2023;108(8):2044–58.PubMedPubMedCentralCrossRef
51.
Nishiyama A, Nakanishi M. Navigating the DNA methylation landscape of cancer. Trends Genet. 2021;37(11):1012–27.PubMedCrossRef
52.
Papanicolau-Sengos A, Aldape K. DNA methylation profiling: an emerging paradigm for Cancer diagnosis. Annu Rev Pathol. 2022;17:295–321.PubMedCrossRef
53.
Heichman KA, Warren JD. DNA methylation biomarkers and their utility for solid cancer diagnostics. Clin Chem Lab Med. 2012;50(10):1707–21.PubMedCrossRef
54.
Smith J, Sen S, Weeks RJ, Eccles MR, Chatterjee A. Promoter DNA hypermethylation and paradoxical gene activation. Trends Cancer. 2020;6(5):392–406.PubMedCrossRef
55.
Gold B. Somatic mutations in cancer: stochastic versus predictable. Mutat Res Genet Toxicol Environ Mutagen. 2017;814:37–46.PubMedCrossRef
56.
57.
Lang F, Schrörs B, Löwer M, Türeci Ö, Sahin U. Identification of neoantigens for individualized therapeutic cancer vaccines. Nat Rev Drug Discov. 2022;21(4):261–82.PubMedPubMedCentralCrossRef
58.
Sha D, Jin Z, Budczies J, Kluck K, Stenzinger A, Sinicrope F. Tumor Mutational Burden as a predictive biomarker in solid tumors. Cancer Discov. 2020;10(12):1808–25.PubMedPubMedCentralCrossRef
59.
Chang L, Chang M, Chang HM, Chang F. Microsatellite instability: a predictive biomarker for cancer immunotherapy. Appl Immunohistochem Mol Morphol. 2018;26(2):e15–21.PubMedCrossRef
60.
Goodman AM, Sokol ES, Frampton GM, Lippman SM, Kurzrock R. Microsatellite-stable tumors with high mutational burden benefit from immunotherapy. Cancer Immunol Res. 2019;7(10):1570–3.PubMedPubMedCentralCrossRef
61.
Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011;331(6024):1565–70.ADSPubMedCrossRef
62.
Raskov H, Orhan A, Christensen JP, Gögenur I. Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. Br J Cancer. 2021;124(2):359–67.PubMedCrossRef
63.
64.
Nakayama T, Hirahara K, Onodera A, Endo Y, Hosokawa H, Shinoda K, Tumes DJ, Okamoto Y. Th2 cells in health and disease. Annu Rev Immunol. 2017;35:53–84.PubMedCrossRef
65.
Kidd P. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern Med Rev. 2003;8(3):223–46.PubMed
66.
McLane LM, Abdel-Hakeem MS, Wherry EJ. CD8 T cell exhaustion during chronic viral infection and Cancer. Annu Rev Immunol. 2019;37:457–95.PubMedCrossRef
67.
Huang Y, Jia A, Wang Y, Liu G. CD8(+) T cell exhaustion in anti-tumour immunity: the new insights for cancer immunotherapy. Immunology. 2023;168(1):30–48.PubMedCrossRef
68.
69.
Tietscher S, Wagner J, Anzeneder T, Langwieder C, Rees M, Sobottka B, de Souza N, Bodenmiller B. A comprehensive single-cell map of T cell exhaustion-associated immune environments in human breast cancer. Nat Commun. 2023;14(1):98.ADSPubMedPubMedCentralCrossRef
70.
71.
Wang Y, Xiang Y, Xin VW, Wang XW, Peng XC, Liu XQ, Wang D, Li N, Cheng JT, Lyv YN, et al. Dendritic cell biology and its role in tumor immunotherapy. J Hematol Oncol. 2020;13(1):107.PubMedPubMedCentralCrossRef
72.
Bagchi S, Yuan R, Engleman EG. Immune Checkpoint inhibitors for the treatment of Cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223–49.PubMedCrossRef
73.
Shen W, Gong B, Xing C, Zhang L, Sun J, Chen Y, Yang C, Yan L, Chen L, Yao L, et al. Comprehensive maturity of nuclear pore complexes regulates zygotic genome activation. Cell. 2022;185(26):4954-4970e4920.PubMedCrossRef
74.
Schwartz M, Travesa A, Martell SW, Forbes DJ. Analysis of the initiation of nuclear pore assembly by ectopically targeting nucleoporins to chromatin. Nucleus. 2015;6(1):40–54.PubMedPubMedCentralCrossRef
75.
Scholz BA, Sumida N, de Lima CDM, Chachoua I, Martino M, Tzelepis I, Nikoshkov A, Zhao H, Mehmood R, Sifakis EG, et al. WNT signaling and AHCTF1 promote oncogenic MYC expression through super-enhancer-mediated gene gating. Nat Genet. 2019;51(12):1723–31.PubMedCrossRef
76.
Rayala HJ, Kendirgi F, Barry DM, Majerus PW, Wente SR. The mRNA export factor human Gle1 interacts with the nuclear pore complex protein Nup155. Mol Cell Proteom. 2004;3(2):145–55.CrossRef
77.
Lin DH, Correia AR, Cai SW, Huber FM, Jette CA, Hoelz A. Structural and functional analysis of mRNA export regulation by the nuclear pore complex. Nat Commun. 2018;9(1):2319.ADSPubMedPubMedCentralCrossRef
78.
Culjkovic-Kraljacic B, Baguet A, Volpon L, Amri A, Borden KL. The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation. Cell Rep. 2012;2(2):207–15.PubMedPubMedCentralCrossRef
79.
Fellenberg J, Sähr H, Kunz P, Zhao Z, Liu L, Tichy D, Herr I. Restoration of mir-127-3p and miR-376a-3p counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells by targeting COA1, GLE1 and PDIA6. Cancer Lett. 2016;371(1):134–41.PubMedCrossRef
80.
Tzschach A, Grasshoff U, Schäferhoff K, Bonin M, Dufke A, Wolff M, Haas-Lude K, Bevot A, Riess O. Interstitial 9q34.11-q34.13 deletion in a patient with severe intellectual disability, hydrocephalus, and cleft lip/palate. Am J Med Genet A. 2012;158a(7):1709–12.PubMedCrossRef
81.
Liu Z, Zhang Y, Xie J, Li C, Wang X, Shen J, Zhang Y, Wang S, Cheng N. Regenerating gene 1B silencing inhibits colon cancer cell HCT116 proliferation and invasion. Int J Biol Markers. 2015;30(2):e217-225.PubMedCrossRef
82.
Zhou Q, Li J, Ge C, Chen J, Tian W, Tian H. SNX5 suppresses clear cell renal cell carcinoma progression by inducing CD44 internalization and epithelial-to-mesenchymal transition. Mol Ther Oncolytics. 2022;24:87–100.PubMedCrossRef
83.
Zhou Q, Huang T, Jiang Z, Ge C, Chen X, Zhang L, Zhao F, Zhu M, Chen T, Cui Y, et al. Upregulation of SNX5 predicts poor prognosis and promotes hepatocellular carcinoma progression by modulating the EGFR-ERK1/2 signaling pathway. Oncogene. 2020;39(10):2140–55.PubMedCrossRef
84.
Cheng S, Douglas-Jones A, Yang X, Mansel RE, Jiang WG. Transforming acidic coiled-coil-containing protein 2 (TACC2) in human breast cancer, expression pattern and clinical/prognostic relevance. Cancer Genomics Proteom. 2010;7(2):67–73.
85.
Shakya M, Zhou A, Dai D, Zhong Q, Zhou Z, Zhang Y, Li X, Bholee AK, Chen M. High expression of TACC2 in hepatocellular carcinoma is associated with poor prognosis. Cancer Biomark. 2018;22(4):611–9.PubMedPubMedCentralCrossRef
86.
Majidpoor J, Mortezaee K. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives. Clin Immunol. 2021;226: 108707.PubMedCrossRef
87.
88.
Atkins MB, Lee SJ, Chmielowski B, Tarhini AA, Cohen GI, Truong TG, Moon HH, Davar D, O’Rourke M, Stephenson JJ, et al. Combination Dabrafenib and Trametinib versus combination Nivolumab and Ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq Trial-ECOG-ACRIN EA6134. J Clin Oncol. 2023;41(2):186–97.PubMedCrossRef
89.
Long GV, Hauschild A, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, et al. Adjuvant dabrafenib plus Trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017;377(19):1813–23.PubMedCrossRef
90.
Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future. Pharmacol Ther. 2020;206: 107447.PubMedCrossRef
91.
Zhao S, Tang Y, Wang R, Najafi M. Mechanisms of cancer cell death induction by paclitaxel: an updated review. Apoptosis. 2022;27(9–10):647–67.PubMedCrossRef
92.
Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N. Triple-negative breast cancer–current status and future directions. Ann Oncol. 2009;20(12):1913–27.PubMedCrossRef
93.
Vagia E, Mahalingam D, Cristofanilli M. The Landscape of targeted therapies in TNBC. Cancers (Basel). 2020;12(4):916.PubMedCrossRef
94.
95.
Bai X, Ni J, Beretov J, Graham P, Li Y. Triple-negative breast cancer therapeutic resistance: where is the Achilles’ heel? Cancer Lett. 2021;497:100–11.PubMedCrossRef
96.
Tray N, Taff J, Adams S. Therapeutic landscape of metaplastic breast cancer. Cancer Treat Rev. 2019;79:101888.PubMedCrossRef
97.
So JY, Ohm J, Lipkowitz S, Yang L. Triple negative breast cancer (TNBC): non-genetic tumor heterogeneity and immune microenvironment: emerging treatment options. Pharmacol Ther. 2022;237: 108253.PubMedPubMedCentralCrossRef
Metadata
Title
Pan-cancer analysis of NUP155 and validation of its role in breast cancer cell proliferation, migration, and apoptosis
Authors
Zi-qiong Wang
Zhi-xuan Wu
Zong-pan Wang
Jing-xia Bao
Hao-dong Wu
Di-yan Xu
Hong-feng Li
Yi-Yin Xu
Rong-xing Wu
Xuan-xuan Dai
Publication date
01-12-2024
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2024
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-024-12039-6

Other articles of this Issue 1/2024

BMC Cancer 1/2024 Go to the issue

Research

Association of hormone receptors and human epidermal growth factor receptor-2/neu expressions with clinicopathologic factors of breast carcinoma: a cross-sectional study in a tertiary care hospital, Kabul, Afghanistan

Research

Adult head and neck rhabdomyosarcoma: radiotherapy- based treatment, outcomes, and predictors of survival

Research

Prognostic significance of multiparametric flow cytometry minimal residual disease at two time points after induction in pediatric acute myeloid leukemia

Research

Tretinoin improves the anti-cancer response to cyclophosphamide, in a model-selective manner

Research

Causal association of sleep traits with the risk of thyroid cancer: A mendelian randomization study

Research

Diagnostic value of applying preoperative breast ultrasound and clinicopathologic features to predict axillary lymph node burden in early invasive breast cancer: a study of 1247 patients
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits